Aprio Wealth Management LLC Buys New Shares in GSK plc (NYSE:GSK)

Aprio Wealth Management LLC purchased a new stake in GSK plc (NYSE:GSK) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,933 shares of the pharmaceutical company’s stock, valued at approximately $202,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. JTC Employer Solutions Trustee Ltd lifted its stake in shares of GSK by 71.3% in the first quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company’s stock valued at $909,063,000 after buying an additional 8,800,822 shares during the period. Primecap Management Co. CA raised its holdings in GSK by 13.9% in the 2nd quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company’s stock valued at $558,689,000 after acquiring an additional 1,773,020 shares in the last quarter. Mondrian Investment Partners LTD lifted its position in shares of GSK by 37.8% in the 1st quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company’s stock worth $236,250,000 after acquiring an additional 1,512,442 shares during the period. Fisher Asset Management LLC lifted its position in shares of GSK by 10.6% in the 4th quarter. Fisher Asset Management LLC now owns 15,036,881 shares of the pharmaceutical company’s stock worth $557,267,000 after acquiring an additional 1,436,488 shares during the period. Finally, Acadian Asset Management LLC grew its holdings in shares of GSK by 180.0% during the 1st quarter. Acadian Asset Management LLC now owns 2,219,798 shares of the pharmaceutical company’s stock worth $95,129,000 after purchasing an additional 1,426,935 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Trading Down 1.6 %

Shares of GSK stock opened at $38.03 on Wednesday. GSK plc has a 12-month low of $33.67 and a 12-month high of $45.92. The stock has a market capitalization of $78.82 billion, a P/E ratio of 13.78, a price-to-earnings-growth ratio of 1.31 and a beta of 0.65. The company has a 50-day simple moving average of $41.54 and a 200 day simple moving average of $41.47. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The company had revenue of $9.95 billion during the quarter, compared to analyst estimates of $9.49 billion. Research analysts expect that GSK plc will post 4.17 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be given a $0.3843 dividend. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, August 16th. This represents a $1.54 annualized dividend and a yield of 4.04%. GSK’s payout ratio is presently 54.71%.

Insiders Place Their Bets

In other GSK news, major shareholder Plc Gsk bought 2,791,930 shares of the stock in a transaction dated Friday, September 27th. The stock was bought at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the purchase, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 10.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on GSK. Jefferies Financial Group upped their target price on GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Argus upgraded shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. UBS Group cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Finally, Citigroup upgraded shares of GSK to a “strong-buy” rating in a research note on Monday, June 24th. Four equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, GSK presently has an average rating of “Buy” and an average target price of $50.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.